MINIREVIEW
G Protein-coupled Receptors
I. DIVERSITY OF RECEPTOR-LIGAND INTERACTIONS*

Tae H. JiDagger §, Mathis Grossmann, and Inhae JiDagger

From the Dagger  Department of Molecular Biology, University of Wyoming, Laramie, Wyoming 82071-3944 and  Walter and Eliza Hall Institute, Melbourne, Australia

    INTRODUCTION
Top
Introduction
References

Nearly 2000 G protein-coupled receptors (GPCRs)1 have been reported since bovine opsin was cloned in 1983 (1) and the beta -adrenergic receptor in 1986 (2). They are classified into over 100 subfamilies according to the sequence homology, ligand structure, and receptor function. A substantial degree of amino acid homology is found among members of a particular subfamily, but comparisons between subfamilies show significantly less or no similarity.

Mutations have been observed that relate to a wide spectrum of hereditary and somatic disorders and diseases from cancer to infertility. These mutant receptors are incapable of binding ligand or generating normal signals, constitutively generate signals, or are not appropriately expressed on the cell surface. On the other hand, some mutations are beneficial. For example, a mutation in a chemokine (CCR5) receptor, which is a co-receptor for human immunodeficiency virus (HIV), prevents binding of HIV to target cells and consequently prevents HIV viral infection among the majority of homozygotes with this mutation (3).

Although the majority of GPCRs mediate signal transduction via G proteins, emerging evidence indicates that some of these receptors are also capable of sending signals via alternative signal molecules, e.g. Jak2 kinase, phospholipase Cgamma , or protein kinase C. These alternative pathways are an indication of the overall diversity occurring in the GPCR superfamily. Furthermore, there are putative seven transmembrane molecules, which do not appear to be coupled to a G protein.

The most striking difference has been observed in the sites and modes of ligand binding and signal generation, which not only manifests the diversity but also indicates the availability of numerous alternative approaches to clinical and industrial applications. In this review, we describe the general structure and ligand interactions of the receptors, and in the following review, Kobilka's group (4) focuses on the conformational changes during receptor activation.

    General Structure: N-terminal Segment, Seven TMs, Three Exoloops, Three-Four Cytoloops, and C-terminal Segment

As shown in Fig. 1A, all GPCRs have an extracellular N-terminal segment, seven TMs, which form the TM core, three exoloops, three cytoloops, and a C-terminal segment. A fourth cytoplasmic loop is formed when the C-terminal segment is palmitoylated at Cys. Each of the seven TMs is generally composed of 20-27 amino acids. On the other hand, N-terminal segments (7-595 amino acids), loops (5-230 amino acids), and C-terminal segments (12-359 amino acids) vary in size, an indication of their diverse structures and functions. Interestingly, there is a weak positive correlation between an N-terminal segment's length and ligand size (5), suggesting a role in ligand binding, in particular for large polypeptides and glycoprotein hormones. A notable exception is the ~600-amino acid N-terminal segment of neurotransmitter receptors such as the calcium receptor.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic presentation of the general structure of GPCRs and receptor-ligand interactions. A, general structure and terminology. Several distinct modes have been observed for ligand binding and signal generation at exclusively the TM core for photon, biogenic amines, nucleosides, eicosanoids, and moieties (lysophosphatidic acid and sphingosine 1-phosphate) of lipids (B), and the core, exoloops, and N-terminal segment for peptides of <= 40 amino acids (C). D, protease ligands like thrombin bind to and cleave the N-terminal segment. The resulting shorter N-terminal segment interacts with exoloops to generate a signal, whereas the released peptide binds to platelet to stimulate platelet aggregation. E, glycoprotein hormones, LH, FSH, human CG, and TSH, bind to the ~350-amino acid N-terminal segment and the liganded N-terminal segment interacts with exoloops to generate a signal. F, small neurotransmitters, Ca2+, glutamate, and GABA, bind to the ~600-amino acid N-terminal segment, and the liganded N-terminal segment interacts with the membrane-associated domain, thus generating a signal.

Why Seven TMs?-- The ubiquitous adoption of a seven TM structure raises the inevitable question concerning its structural and functional merits. Odd numbers of TMs place the N- and C-terminal segments at opposite membrane surfaces. It allows glycosylation and ligand binding at the N-terminal segment, and phosphorylation and palmitoylation at the C-terminal segment for desensitization (6) and internalization. Seven TMs may be the minimum necessary to form six loops and a TM core with a sufficient size and versatility to offer a prodigious number of specificities, regulatory mechanisms, and contact sites for G protein and other signal molecules such as Jak2 kinase (7), phospholipase Cgamma (8), GPCR kinases (6), arrestin (6), calmodulin (9), and/or protein kinase C (9). In contrast, five TMs may be insufficient to form a stable yet flexible TM core, whereas nine would be more than enough. For example, ion-gated channel proteins are pentamers of four TM subunits, which form a central hydrophilic channel (5) or a 20-TM monomer (10). In either case, they comprise 20 TMs, and the channel is narrow, excluding ions >5 Å (10). Apparently, four TMs by themselves are not sufficient to form a functional core.

Kinked and Tilted TM alpha -Helices of Unequal Length and Hydrophobicity-- TMs are likely to assume diverse structures. The TMs of bacteriorhodopsin (11) and animal rhodopsin (12) form alpha -helices although some TM of other membrane proteins such as porins have beta  structures (13). TM alpha -helices vary in length and can extend beyond the lipid bilayer. Therefore, the boundaries between TMs and loops are likely to be uneven and may be dynamic. TMs 1, 4, and 7 are significantly more hydrophobic than TMs 2, 3, 5, and 6 that contain several ionic and/or neutral residues. In fact, some of the more hydrophobic TMs 1, 4, and 7 have only one hydrophilic residue such as Asn or Ser. Pro residues are frequently found in TM alpha -helices, unlike alpha -helices in globular proteins. A Pro can kink the helix backbone by ~26° and impact the global structure. Some TM alpha -helices are tilted in the membrane. For example, TM 3 of animal rhodopsin is most tilted by ~30°, whereas TMs 4, 6, and 7 are the least tilted (12). TMs 3, 5, and 6 are suggested to protrude more than the others from the lipid bilayer toward the extracellular surface. TMs often contain Cys residues, and some are believed to be apposed although there is no convincing evidence for a TM disulfide linkage.

Counterclockwise Orientation and Closed Loop Formation of Seven TMs-- The seven TMs of bacteriorhodopsin (11), animal rhodopsin (12), and adrenergic receptors (14) are arranged as a closed loop in the counterclockwise direction from TM 1 to TM 7 when viewed from the extracellular surface (Fig. 1A). The orientation of the TMs imposes a stereo- and geometric specificity on a ligand's entry into and binding to the TM core. In this arrangement, the core is primarily comprised of TMs 2, 3, 5, 6, and perhaps 7, whereas TMs 1 and 4 are peripherally sequestered. In general, TMs 1, 2, and 7 are apposed (15). This arrangement is consistent with the view that the more hydrophobic TMs 1, 4, and 7 are exposed more to the lipid bilayer than the less hydrophobic TMs 2, 3, 5, and 6. It is unknown whether there are GPCRs that are open-looped or not closed between TMs 1 and 7. Different arrangements can provide interesting mechanisms for ligand binding and receptor activation. For example, if TM 7 associates more closely with TM 2 than TM 1, there will be a long crevice between TMs 1 and 7. Such a crevice offers a binding site for the fatty chain of lysophosphatidic acid. Also, TMs 1 and 7 of a GPCR may associate with TMs 1 and 7 of another GPCR to form a dimer.

TMs are entropically driven into the lipid bilayer primarily by water molecules present outside of the membrane. However, it is unclear what forces are primarily responsible for arranging TMs within the lipid bilayer: for example, whether the hydrophilic sides of TMs are entropically driven away from the lipid bilayer, the hydrophobic sides of TMs prefer to associate with the lipid bilayer, or groups in the TM core bond together, e.g. by van der Waals interactions.

TM Core Tightly Packed by Hydrogen Bonds and Salt Bridges-- The recent high resolution three-dimensional structure of bacteriorhodopsin (11) suggests that the TM core does not have a vacant pocket, channel, or tunnel structure, as generally thought. Although the TM core has polar residues and, therefore, is considered hydrophilic, there are only a limited number (~10) of associated water molecules (11). Extensive hydrogen bonds exist between residues of the same TM as well as other TMs like TMs 2 and 7 (11, 15). In addition to hydrogen bonds, conserved TM 2 Asp pairs with TM 1 and TM 7 Asn residues in the TSH-releasing hormone receptor, and conversely, TM 2 Asn with TM 7 Asp in the GnRH receptor (15). Although TMs have Cys residues and some could be paired, no specific pairs have been identified. Because of these interactions, there may not be space for a TM pore in most GPCRs. The core of bacteriorhodopsin is so tightly packed in the basal state that transfer of a proton or water molecule is unlikely (11). This is reminiscent of the observation that the 20-TM ion channels are not large enough for ions >5 Å to pass (10).

Disulfide Bonds-- Disulfides always play a major role in the structure and stability of proteins. Among numerous Cys residues of eukaryotic GPCRs, the two conserved Cys residues in exoloops 1 and 2 are known to be linked by a disulfide in bovine rhodopsin, the TSH-releasing hormone receptor, the thromboxane receptor, and the GnRH receptor. This disulfide is expected to constrain the loops and receptor, specifically pulling exoloop 2 over and thus blocking the extracellular opening of the core. Surprisingly, such a structure is not seen in bacteriorhodopsin, which has no Cys. Instead, exoloop 2 of bacteriorhodopsin is projected away from the core opening and is not near exoloop 1. Furthermore, the two corresponding Cys residues in some GPCRs have been suggested to pair with another Cys rather than with each other (16). Disulfides exist in the N-terminal segment of the glycoprotein hormone receptors (17).

    Ligand Binding and Receptor Activation

Several distinct modes (Fig. 1, B-F) have been observed for high affinity ligand binding to the TM core exclusively (photon, biogenic amines, nucleosides, eicosanoids, and moieties (lysophosphatidic acid and sphingosine 1-phosphate) of lipids), to both the core and exoloops (peptides <= 40 amino acids), to exoloops and N-terminal segment (polypeptides <= 90 amino acids), or exclusively to the N-terminal segment (glycoproteins >= 30 kDa). The distinction between ligand binding and receptor activation is supported by the existence of antagonists that competitively inhibit agonist binding. Further, glycoprotein hormones bind to the N-terminal segment whereas receptors are activated at the membrane-associated domain (5). Interactions of ligands and receptors seem to involve hydrogen bonds, ion pairs, and hydrophobic contacts.

Ligand Binding and Signal Generation in the TM Core

To define better the mechanics of receptor activation it may be divided into at least three steps, signal generation, TM signal transduction, and signal transfer to cytoplasmic signal molecules (5). The simplest way to activate receptors is for a ligand to bind, generate a signal in, and transduce it through the TM core (Fig. 1B). In such a case, changes in TM hydrogen bonds are likely to be the underlying mechanism for signal generation and TM reorganization. For example, photoactivation of retinal straightens its bent configuration and rearranges hydrogen bonds and the packing of TMs 3 and 5-7. In biogenic amine receptors, TM 3 is believed to be the primary site for ligand binding whereas TMs 5 and 6 are the signal generation site. Although initial ligand binding and signal generation are related yet separate phenomena, it is technically difficult to distinguish them. However, a few receptor systems such as glycoprotein hormone receptors and protease-activated receptors are available as good models to distinguish experimentally ligand binding from signal generation and thus investigate the transition between these two steps.

Rhodopsin-- The family of photoreceptors comprises several isoforms specific for red, blue, and green colors. These color characteristics stem from variations in their amino acid sequences. All of them have a retinal chromophore, which is attached through formation of a Schiff's base between the aldehyde moiety of retinal and the epsilon -amine of the Lys in the middle of TM 7 (18). The protonated Schiff's base is paired with conserved Glu113 present at the boundary between TM 3 and exoloop 1, thus bringing TMs 3 and 7 in apposition. Photoaffinity labeling, mutational analysis, and modeling show that the beta -ionone ring of retinal associates with TMs 3, 5, and 6, particularly TM 6 Trp265 and Tyr268 (19). The C9 methyl group of 11-cis-retinal appears to associate with TM 3 Gly121 (19). Light absorption causes a bent 11-cis to linear all-trans isomerization and part of the TM peptide backbone to be exposed. As a result at least one water hydrogen bond is formed (20) and the salt bridge constraint between TM 3 Glu113 and TM 7 Lys296 may break. Because each hydrogen bond energy is worth 3-7 kcal/mol, these changes are likely and sufficient to rearrange TMs, particularly TMs 3, 6 (19), and 7, thereby generating a signal.

Biogenic Amine Receptors-- Biogenic amines, epinephrine, norepinephrine, dopamine, and histamine enter and bind the TM core (4, 18). The amine of catecholamines pairs with the carboxyl group of TM 3 Asp113 of the receptor, 9 Å deep in the core. TM 3 Asp113 is crucial for ligand binding but not for signal generation. The fact that Asp113 could not be replaced with Glu underscores the tight space and importance of the size and orientation of the carboxyl chain. The catechol ring of the ligand is thought to dock the pocket consisting of TMs 5 and 6. Specifically, the meta and para OH groups of the catechol ring appear to hydrogen bond, respectively, to TM 5 Ser204 and Ser207, which lie one alpha -helical turn apart on the same side of the TM alpha -helix. Because this double hydrogen bonding would constrain the TM 5 alpha -helix (18) and/or the ligand and the ligand-linked TM 3 alpha -helix, the TM structure and packing are expected to be adjusted. In fact, the TM 6 structure, particularly Cys285, changes in activated receptors (21), and Phe290 is thought to stabilize the catechol ring (18). Because the interactions of the catechol ring are more important for receptor activation than ligand binding, these changes could generate a signal. In addition, the interaction of TM 3 Asp125 and TM 7 Lys331 may break upon receptor activation (22). For histamine, the amine may ion pair with the TM 3 Asp, whereas the imidazole ring associates with TM 5 Asp and Thr, which correspond to TM 5 Ser204 and Ser207 of catecholamine receptors (18). Acetylcholine also appears to bind similarly the TM core, particularly TMs 5 and 6 for signal generation (18).

Nucleoside and Nucleotide Receptors-- Extracellular adenosine, adenine nucleotides, and urdine nucleotides are capable of binding G protein-coupled metabotropic receptors (P2Y receptors). Studies of metabotropic adenosine receptors suggest that ligands bind primarily in the TM core and exoloops. For the adenosine A1 receptor ligand binding requires TMs 1-4 (23), 6, and 7 as well as exoloop 2 (24). On the other hand, TMs 5-7, particularly Ser277 and His278 of TM 7, are important for ligand binding by the adenosine A2 receptor (25). Signal generation by adenosine receptors appears to require additional unknown ligand contacts, because agonists and antagonists bind the receptors differently. Four subclasses of chemoattractant cAMP receptors are found in Dictyostelium. These receptors are coupled to a G protein that activates adenylyl cyclase. For ligand binding by the cAMP receptor 1, TMs 3, 5, and 6 and exoloop 3 are important, and exoloop 2 appears to modulate ligand access to the TM core binding site (26).

Eicosanoid Receptors-- Eicosanoids are derived from arachidonic acid and have a carboxyl group. This family of lipid hormones, which includes leukotrienes and prostanoids (prostaglandins, prostacyclins, and thromboxanes), binds specific subfamily receptor members of high homology. The ligands bind the TM core, and interactions with TMs 3, 6, and 7 are crucial (27, 28). A conserved TM 7 Arg near the extracellular surface is thought to pair with the carboxyl group of the ligand (27). The structure and orientation of the cyclopentane ring of prostanoids influence receptor specificity (28), suggesting variations in the TM core structure.

Short Peptide Receptors with Ligand Binding Partially in the TM Core and Exoloops

Formyl Receptor-- Tripeptide N-formyl-Met-Leu-Phe is one of the smallest peptide ligands for GPCRs. Spectroscopic and mutational studies (50) show that the N-formyl moiety of the ligand binds in the TM core around TMs 2 and 3, whereas the C-terminal region of the ligands associates with the N-terminal segment and exoloops 1 and 2 (29). Recently, the Val83-Arg84-Lys85 sequence that joins TM2 and exoloop 1 has been shown to be photoaffinity labeled with the ligand (30).

Glycoprotein Hormone-releasing Hormone Receptors-- Mutational analyses of the thyrotropin-releasing hormone (pyroEHP-NH2) receptor show that several amino acids in TM 3 and one in exoloop 2 are important for ligand binding. Mutation and affinity-labeling studies of gonadotropin-releasing hormone suggest the N terminus of GnRH binds the TM core and the C terminus around exoloops 2 and 3. His2 of GnRH is believed to be close to TM 3 Lys121, Arg8 of GnRH to exoloop 3 Asp302, and the C-terminal glycinamide to exoloop 2 Asn102 (15). Also, the N-terminal segment appears to be near the ligand (31). Because TM 3 Lys121 is ~7.5 Å away from the extracellular surface and its side chain could extend to near the surface, GnRH enters, but not deeply into, the TM core.

Angiotensin Receptor-- The hydrophobic C-terminal region of angiotensin II (DRVYIHPF) appears to enter the TM core of the receptor, and the C-terminal carboxyl group pairs with TM 5 Lys199 (32), 7-14 Å from the extracellular surface. On the other hand, Asp-Arg of the DRVYIHPF sequence seems to ion pair with exoloop 2 His183 and exoloop 3 Asp281 of the receptor, respectively (33). The interaction with Asp281 is more crucial for signal generation.

Multistep Contacts at the N-terminal Segment and Exoloops

Receptors for Glucagon, Calcitonin, and Vasoactive Intestinal Peptides-- This class of peptide hormones is 30-40 amino acids long. On the other hand, the N-terminal segments of their receptors are 116-147 amino acids long and primarily responsible, but not sufficient, for high affinity ligand binding, as exoloops also appear to be required (34). Partial entry of the ligand into the TM core is a possibility. Gly10-Arg24 of calcitonin is essential for interaction with the N-terminal segment of the receptor. The resulting transient hormone-receptor complex, including particularly the N-terminal 10 residues of calcitonin, may make secondary contact with exoloops and generate a signal (34). In the glucagon receptor, Asp126-Lys137 of the 145-amino acid N-terminal segment and exoloop 1 are crucial for ligand binding (35).

Parathyroid Hormone (PTH) Receptors-- The C-terminal region of 84-amino acid PTH is important for receptor binding, whereas the N-terminal region is crucial for receptor activation. For the receptor, ligand specificity resides primarily in the N-terminal segment whereas signal is generated in the membrane-associated domain, particularly involving TM 3 Ile244 and exoloop 2 Tyr318 (36). These results suggest the two-step interaction of PTH and the receptor, first to form the transient PTH-N-terminal segment complex and next for the complex to interact with the membrane-associated domain to generate a signal.

Initial Ligand Binding at the N-terminal Segment and Subsequent Secondary Contact of the N-terminal Segment with Exoloops

Protease-activated Receptors-- This family of receptors for thrombin and other proteases is activated by proteolysis of the N-terminal segment (37). The protease thrombin recognizes the sequence L38DPRSFLLRNPNDKYEPF55 in the 74-amino acid N-terminal segment of the thrombin receptor and cleaves it at the thrombin cleavage sequence, L38DPRdown-arrow S42. The N-terminal segment is sufficient for the proteolysis by thrombin, and the released peptide, Met1-Arg41, is a strong agonist to stimulate platelet aggregation (38). At the same time, the resulting new 33-amino acid N-terminal segment acts as a tethered ligand and intramolecularly binds to exoloops of the remaining receptor; in particular Arg5 of the new N-terminal segment interacts with exoloop 2 Glu260 to generate the signal (39). Protease-activated receptor 2 is structurally similar to thrombin receptors and is cleaved at R36down-arrow S37 in the N-terminal segment. The resulting new N-terminal segment contacts exoloops, most likely between the conserved Arg of the N-terminal segment and Glu in exoloop 2 (40).

Glycoprotein Hormone Receptors-- The glycoprotein hormone receptors consist of two roughly equal domains, a 350-400-residue N-terminal segment and a ~300-amino acid membrane-associated domain. The N-terminal segment alone is capable of high affinity ligand binding whereas the membrane-associated domain is the site of receptor activation (5). The N-terminal segment has 8-9 Leu-rich repeats. These Leu-rich repeats are thought to form a crescent with the concave inner surface consisting of beta -sheets, which may bind ligands (41, 42). In addition to the Leu-rich crescent, the N-terminal region of the N-terminal segment contacts the hormone (43). Although the N-terminal segment alone is capable of high affinity ligand binding, this is modulated by exoloops of the receptor (44).

Glycoprotein hormones, LH, FSH, CG, and TSH, are the largest (30-40 kDa) and most complex GPCR agonists. They are heterodimers of a common alpha -subunit and a hormone-specific beta -subunit. These hormones initially bind exclusively to the N-terminal segment with high affinity. The hormone-N-terminal segment complex undergoes conformational changes (45) and makes secondary interactions with the membrane-associated domain, thus generating a signal (5). The initial high affinity interaction includes multiple contacts between the N-terminal segment and both subunits of the hormone (41, 42). They involve the alpha  C-terminal region, the N-oligosaccharide at alpha Asn52, and a unique alpha -helix in the alpha -subunit, as well as an unusual loop (seat belt) in the beta -subunit and the peripheral beta -hairpin loops of both subunits (41). Secondary contacts occur between the liganded N-terminal segment and exoloops 1-3 (5, 44, 46). Signal is, therefore, likely generated at exoloops. In fact, some mutations in exoloops 1-3 result in constitutive activation (47).

Neurotransmitter Receptors-- This family of receptors is noted for the longest N-terminal segments (~600 amino acids) that recognize glutamate, gamma -aminobutyric acid (GABA), and calcium/cations.

For metabotropic glutamate receptors, the N-terminal half of the ~600-amino acid N-terminal segment not only provides the ligand binding site and specificity but also indicates the signal specificity for activation of phospholipase C or inhibition of adenylyl cyclase (48). Some metabotropic glutamate receptors bind calcium as well as glutamate, and Ser166 appears to be important (49). The structure and size of the GABAB and calcium receptor are similar to those of the metabotropic glutamate receptors. Therefore, they are expected to similarly bind ligands and be activated.

    Conclusions and Future Directions

An increasing number of GPCR subfamilies shows diverse modes of ligand binding, signal generation, TM signal transduction, and signal transfer to various cytoplasmic signal molecules other than G protein, such as Jak2 kinase (7), phospholipase Cgamma (8), and protein kinase C (9). Therefore, the question rises whether these distinct responses are induced by a single signal originating from a single receptor or by separate signals generated by a single receptor or different receptors. If a single receptor is capable of activating one or more effectors, does it activate them simultaneously or only one at a time? The general underlying mechanisms appear to involve changes in interactions and conformation, particularly hydrogen bonds, salt bridges, TM rearrangement, and perhaps receptor oligomerization (4).

    ACKNOWLEDGEMENTS

We thank Drs. Hanlee Ji, Kurt W. Miller, Brian K. Kobilka, Martha Vaughan, Peter Nollert, Ehud M. Landua, and Lee E. Limbird for helpful comments.

    FOOTNOTES

* This minireview will be reprinted in the 1997 Minireview Compendium, which will be available in December, 1997. This is the first article of three in the "G Protein-coupled Receptors Minireview Series." This work was supported by Grants HD-18702 and DK-51469 from the National Institutes of Health.

§ To whom correspondence should be addressed. Tel.: 307-766-6272; Fax: 307-766-5098; E-mail: Ji{at}uwyo.edu.

1 The abbreviations used are: GPCR, G protein-coupled receptor; HIV, human immunodeficiency virus; TM, transmembrane domain; N-terminal segment, extracellular N-terminal domain; exoloop, extracellular loop; cytoloop, cytoplasmic loop; C-terminal segment, cytoplasmic C-terminal segment; TSH, thyroid-stimulating hormone; PTH, parathyroid hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; CG, choriogonadotropin; GABA, gamma -aminobutyric acid.

    REFERENCES
Top
Introduction
References

  1. Nathans, J., and Hogness, D. S. (1983) Cell 34, 807-814[Medline] [Order article via Infotrieve]
  2. Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. D., Rands, E., Diehl, R. E., et al.. (1986) Nature 321, 75-79[Medline] [Order article via Infotrieve]
  3. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R. M., MacDonald, M. E., Stuhlmann, H., Koup, R. A., and Landau, N. R. (1996) Cell 86, 367-377[Medline] [Order article via Infotrieve]
  4. Gether, U., and Kobilka, B. (1998) J. Biol. Chem. 273, 17979-17982[Free Full Text]
  5. Ji, T. H., Murdoch, W. J., and Ji, I. (1995) Endocrine 3, 187-194
  6. Lefkowitz, R. (1998) J. Biol. Chem. 273, 18677-18680[Free Full Text]
  7. Ali, M., Sayeski, P., Dirksen, L., Hayzer, D., Marrero, M., and Bernstein, K. (1997) J. Biol. Chem. 272, 23382-23388[Abstract/Free Full Text]
  8. Marrero, M., Venema, R., Ju, H., Venema, V., Schiefer, B., Harp, J., Ling, B., and Eaton, D. (1998) J. Biol. Chem. 273, 7703-7708[Abstract/Free Full Text]
  9. Minakami, R., Jinnai, N., and Sugiyama, H. (1997) J. Biol. Chem. 272, 20291-20298[Abstract/Free Full Text]
  10. Stryer, L. (1995) Biochemistry, 4th Ed., pp. 300-302, Freeman and Co., New York
  11. Pebay-Peyroula, E., Rummel, G., Rosenbusch, J., and Landau, E. (1997) Science 277, 1676-1681[Abstract/Free Full Text]
  12. Unger, V., Hargrave, P., Baldwin, J., and Schertler, G. (1997) Nature 389, 203-206[CrossRef][Medline] [Order article via Infotrieve]
  13. Schirmer, T., Keller, T., Wang, Y., and Rosenbusch, J. (1995) Science 267, 512-514[Medline] [Order article via Infotrieve]
  14. Mizobe, T., Mervyn Maze, M., Lam, V., Suryanarayana, S., and Kobilka, B. (1996) J. Biol. Chem. 271, 2387-2389[Abstract/Free Full Text]
  15. Sealfon, S., Weinstein, H., and Millar, R. (1997) Endocr. Rev. 18, 180-205[Abstract/Free Full Text]
  16. Couet, J., Sar, S., Jolivet, A., Vu Hai, M.-T., Milgrom, E., and Misrahi, M. (1996) J. Biol. Chem. 271, 4545-4552[Abstract/Free Full Text]
  17. Zhang, R., Buczko, E., and Dufau, M. (1996) J. Biol. Chem. 271, 5755-5760[Abstract/Free Full Text]
  18. Strader, C. D., Fong, T. M., Tota, M. R., Underwood, D., and Dixon, R. A. (1994) Annu. Rev. Biochem. 63, 101-132[CrossRef][Medline] [Order article via Infotrieve]
  19. Han, M., Groesbeek, M., Sakmar, T., and Smith, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13442-13447[Abstract/Free Full Text]
  20. Rath, P., Delange, F., Degrip, W., and Rothschild, K. (1998) Biochem. J. 329, 713-717[Medline] [Order article via Infotrieve]
  21. Javitch, J., Fu, D., Liapakis, G., and Chen, J. (1997) J. Biol. Chem. 272, 18546-18549[Abstract/Free Full Text]
  22. Porter, J. E., Hwa, J., and Perez, D. M. (1996) J. Biol. Chem. 271, 28318-28323[Abstract/Free Full Text]
  23. Rivkees, S., Lasbury, M., and Barbhaiya, H. (1995) J. Biol. Chem. 270, 20485-20490[Abstract/Free Full Text]
  24. Olah, M., Jacobson, K., and Stiles, G. (1994) J. Biol. Chem. 269, 24692-24698[Abstract/Free Full Text]
  25. Kim, J., Wess, J., van Rhee, A., Schöneberg, T., and Jacobson, K. (1995) J. Biol. Chem. 270, 13987-13997[Abstract/Free Full Text]
  26. Kim, J.-Y., Caterina, M., Milne, L., Lin, K., Borleis, J., and Devreotes, P. (1997) J. Biol. Chem. 272, 2060-2068[Abstract/Free Full Text]
  27. Funk, C., Furci, L., Moran, N., and Fitzgerald, G. (1993) Mol. Pharmacol. 44, 934-939[Abstract]
  28. Kobayashi, T., Kiriyama, M., Hirata, T., Hirata, M., Ushikubi, F., and Narumiya, S. (1997) J. Biol. Chem. 272, 15154-15160[Abstract/Free Full Text]
  29. Perez, H., Vilander, L., Andrews, W., and Holmes, R. (1994) J. Biol. Chem. 269, 22485-22487[Abstract/Free Full Text]
  30. Mills, J. S., Miettinen, H. M., Barnidge, D., Vlases, M. J., Wimer-Mackin, S., Dratz, E. A., Sunner, J., and Jesaitis, A. J. (1998) J. Biol. Chem. 273, 10428-10435[Abstract/Free Full Text]
  31. Davidson, J., Assefa, D., Pawson, A., Davies, P., Hapgoo, D. J., Becker, I., Flanagan, C., Roeske, R., and Millar, R. (1997) Biochemistry 36, 12881-12889[CrossRef][Medline] [Order article via Infotrieve]
  32. Noda, K., Saad, Y., Kinoshita, A., Boyle, T., Graham, R., Husain, A., and Karnik, S. (1995) J. Biol. Chem. 270, 2284-2289[Abstract/Free Full Text]
  33. Fen, G. Y., Noda, K., Saad, Y., Liu, X., Husain, A., and Karnik, S. (1995) J. Biol. Chem. 270, 12846-12850[Abstract/Free Full Text]
  34. Stroop, S., Nakamuta, H., Kuestner, R., Moore, E., and Epand, R. (1996) Endocrinology 137, 4752-4756[Abstract]
  35. Unson, C., Cypess, A., Wu, C., Goldsmith, P., Merrifield, R., and Sakmar, T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 310-315[Abstract/Free Full Text]
  36. Bergwitz, C., Jusseaume, S., Luck, M., Juppner, H., and Gardella, T. (1997) J. Biol. Chem. 272, 28861-28868[Abstract/Free Full Text]
  37. Vu, T., Hung, D., Wheaton, V., and Coughlin, S. (1991) Cell 64, 1057-1068[Medline] [Order article via Infotrieve]
  38. Furman, M., Liu, L., Benoit, S., Becker, R., Barnard, M., and Michelson, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3082-3087[Abstract/Free Full Text]
  39. Nanevicz, T., Wang, L., Chen, M., Ishii, M., and Coughlin, S. (1996) J. Biol. Chem. 271, 702-706[Abstract/Free Full Text]
  40. Lerner, D. J., Chen, M., Tram, T., and Coughlin, S. R. (1996) J. Biol. Chem. 271, 13943-13947[Abstract/Free Full Text]
  41. Grossmann, M., Weintraub, B., and Szkudlinski, M. (1997) Endocr. Rev. 18, 476-501[Abstract/Free Full Text]
  42. Dias, J. A., Lindau-Shepard, B., Hauer, C., and Auger, I. (1998) Biol. Reprod. 58, 1331-1336[Medline] [Order article via Infotrieve]
  43. Phang, T., Kundu, G., Hong, S., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 13841-13847[Abstract/Free Full Text]
  44. Ryu, K., Lee, H., Kim, S., Beauchamp, J., Tung, C., Isaacs, N. W., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 6285-6291[Abstract/Free Full Text]
  45. Ji, I., Pan, Y.-N., Lee, Y.-M., Phang, T., and Ji, T. H. (1995) Endocrine 3, 907-911
  46. Remy, J. J., Couture, L., Pantel, J., Haertle, T., Rabesona, H., Bozon, V., Pajot-Augy, E., Robert, P., Troalen, F., Salesse, R., and Bidart, J. M. (1996) Mol. Cell. Endocrinol. 125, 79-91[CrossRef][Medline] [Order article via Infotrieve]
  47. Parma, J., Van Sande, J., Swillens, S., Tonacchera, M., Dumont, J., and Vassart, G. (1995) Mol. Endocrinol. 9, 725-733[Abstract]
  48. Takahashi, K., Tsuchida, K., Tanabe, Y., Masu, M., and Nakanishi, S. (1993) J. Biol. Chem. 268, 19341-19345[Abstract/Free Full Text]
  49. Kubo, Y., Miyashita, T., and Murata, Y. (1998) Science 279, 1722-1725[Abstract/Free Full Text]
  50. Fay, S. P., Domalewski, M. D., and Sklar, L. A. (1993) Biochemistry 32, 1627-1631[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.